Schoen Eric purchased $8K of FLNA

Schoen Eric (Chief Financial Officer) purchased 20,000 shares of FILANA THERAPEUTICS, INC. (FLNA) at $0.42 on 2026-11-16.

Original reporting
SEC EDGAR · Schoen Eric
Published Nov 18, 2026, 9:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 9:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$FLNA
Bullish
medium confidence
Mentioned
$FLNA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FLNABullishLow
01

Why it matters

An officer open-market purchase can be read as bullish sentiment, but the disclosed dollar value is small and lacks additional corroborating catalysts (no guidance, trial, deal, or financing details).

02

Market read

Traders may note the insider buy for sentiment, but the filing alone is unlikely to change valuation expectations materially.

03

What to watch

No 10b5-1 plan is noted, but the article does not provide context on prior holdings, option exercises, or whether other insiders are buying or selling.

Relevance 4/10Novelty 5/10Timing: filed 2026-11-18, transaction dated 2026-11-16

Background

The article is an SEC Form 4 insider transaction disclosure for Filana Therapeutics, Inc. (FLNA).

Company-level read

Ticker impact

$FLNABullishMedium confidence
Context

SEC Form 4 shows CFO Eric Schoen bought 20,000 shares at $0.4200 on 2026-11-16, totaling $8,400, with no 10b5-1 plan.

Expected impact

Likely limited upside bias as traders may view the purchase as confidence, but the small size reduces probability of a sustained move.

Evidence & confidence

The filing is a primary-source insider transaction, but the transaction value ($8.4k) is small and there is no 10b5-1 plan, which can increase interpretive noise rather than create a clear catalyst.

Market effects

No sector-wide implications; this is a single-company insider transaction.

None indicated.

None indicated.

Counterpoint

The purchase could be routine compensation-related liquidity management or personal diversification, and the small size may not reflect a strong forward view.

Key entities

  • FLNA

    Filana Therapeutics, Inc., issuer of the Form 4 insider transaction.

  • Eric Schoen

    Chief Financial Officer reported as the insider purchasing shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$FLNAMed

Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update – Patient screening in Phase 2a study of simufilam in TSC-related epilepsy expected to begin by Q1 2027, following recent lift of FDA clinical hold – Recent publication in Cells 1 prov

$FLNAMedAI 8/10

Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Regulation FD Disclosure. EXHIBIT 99.1 Filana Therapeutics Announces FDA Lift of Clinical Hold on Simufilam, Enabling Phase 2a Study in TSC-Related Epilepsy Patient screening for the Phase 2a study is expected to begin by the first quarter of 2027 Filana has engaged a leading clinical research organizatio

$FLNAMed

Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update

FILANA THERAPEUTICS, INC. (FLNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Filana Therapeutics Reports Q2 2026 Financial Results and Provides Business Update AUSTIN, Texas, July 29, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company currently focused on developing